JPMorgan Chase & Co. Raises Qiagen (NYSE:QGEN) Price Target to $54.00

Qiagen (NYSE:QGENFree Report) had its price objective hoisted by JPMorgan Chase & Co. from $52.00 to $54.00 in a research report released on Tuesday morning, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the stock.

Separately, Stifel Nicolaus cut their price target on shares of Qiagen from $55.00 to $45.00 and set a hold rating on the stock in a report on Wednesday, May 1st. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of Moderate Buy and an average price target of $51.17.

Check Out Our Latest Report on Qiagen

Qiagen Price Performance

QGEN opened at $41.89 on Tuesday. Qiagen has a 1 year low of $34.74 and a 1 year high of $47.70. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.45 and a current ratio of 1.84. The company’s 50 day simple moving average is $43.03 and its 200 day simple moving average is $43.64. The stock has a market capitalization of $9.56 billion, a PE ratio of 28.09, a P/E/G ratio of 3.63 and a beta of 0.42.

Qiagen (NYSE:QGENGet Free Report) last issued its earnings results on Monday, April 29th. The company reported $0.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.02. Qiagen had a return on equity of 12.59% and a net margin of 17.38%. The business had revenue of $459.00 million during the quarter, compared to analysts’ expectations of $453.91 million. During the same quarter in the previous year, the business earned $0.53 EPS. The company’s revenue for the quarter was down 5.4% on a year-over-year basis. As a group, sell-side analysts expect that Qiagen will post 2.13 EPS for the current year.

Institutional Investors Weigh In On Qiagen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Riverview Trust Co bought a new stake in Qiagen in the first quarter valued at about $28,000. Tower Research Capital LLC TRC increased its stake in shares of Qiagen by 66.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 710 shares of the company’s stock valued at $31,000 after acquiring an additional 283 shares during the last quarter. Park Place Capital Corp acquired a new stake in shares of Qiagen in the 1st quarter valued at approximately $36,000. Quarry LP bought a new position in Qiagen during the 4th quarter worth approximately $38,000. Finally, Toronto Dominion Bank acquired a new position in Qiagen during the third quarter valued at approximately $41,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Company Profile

(Get Free Report)

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.

See Also

Analyst Recommendations for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.